Literature DB >> 2902941

Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.

N A Lass1, D Glock, L I Goldberg.   

Abstract

Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering blood pressure, similar to the effects of DA (1 and 2 micrograms/kg/min). Administration of fenoldopam with only DA (1 microgram/kg/min) produced further increase in renal blood flow. After administration of phenoxybenzamine (15 mg/kg i.v.), DA produced significant increments in renal blood flow and reductions in renal vascular resistance when compared with experiments without phenoxybenzamine, suggesting even low dosages of DA exert alpha-adrenoceptor agonist activity. Dobutamine (2 and 4 micrograms/kg/min) increased renal blood flow about 37% of that produced by DA. Fenoldopam added to dobutamine produced similar increments in renal blood flow as DA. Fenoldopam did not affect the increase in cardiac contractile force produced by DA and dobutamine. Thus, fenoldopam alone or in combination with DA had no advantage over 2 and 4 micrograms/kg/min DA to further increase renal blood flow. In contrast, fenoldopam with dobutamine produced greater increments in cardiac contractile force than DA and equivalent increases in renal blood flow as DA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902941     DOI: 10.1161/01.cir.78.5.1310

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs.

Authors:  C A Bloom; M A Labato; S Hazarika; M H Court
Journal:  J Vet Pharmacol Ther       Date:  2011-07-06       Impact factor: 1.786

Review 3.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Inhibition of tubuloglomerular feedback by the D1 agonist fenoldopam in chronically salt-loaded rats.

Authors:  D A Häberle; B Königbauer
Journal:  J Physiol       Date:  1991-09       Impact factor: 5.182

5.  Intravenous fenoldopam infusion in severe heart failure.

Authors:  J J Patel; A S Mitha; P Sareli; J B de Vaal
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 6.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

7.  Effect of Fenoldopam Continuous Infusion on Glomerular Filtration Rate and Fractional Excretion of Sodium in Healthy Dogs.

Authors:  K L Kelly; K J Drobatz; J D Foster
Journal:  J Vet Intern Med       Date:  2016-07-25       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.